China Human Vaccine Industry Report, 2011-2012
  • May/2012
  • Hard Copy
  • USD $2,500
  • Pages:127
  • Single User License
    (PDF Unprintable)       
  • USD $2,400
  • Code: ZYM026
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,800
  • Hard Copy + Single User License
  • USD $2,700
After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release quantity of human vaccine footed up to roughly 770 million person-portions, with market size reaching around RMB1 billion. Moreover, being restricted by the barriers such as vaccine industry policy, technology and capital, it is not easy for companies to set foot in this field and the industry has been with high profitability as a whole. From 2007 to 2011, the gross margin of vaccine business of major manufacturers basically maintained above 60%, and some enterprises such as Walvax Biotechnology and Liaoning Chengda even enjoyed the gross margin of as high as 90% or so.

Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2011

Although Japanese Encephalitis Vaccine, Hepatitis A Vaccine and Influenza Vaccine have been exported to other countries, they are mainly consumed in China. However, China’s vaccine supervisory system was approved by the WHO in March 2011, which may eventually open the door for Chinese vaccines to be distributed globally. In 2011, Tiantan Biological signed a cooperation agreement on oral polio vaccine (OPV) with Bill & Melinda Gates Foundation, according to which, the company will annually supply 160 million OPV doses for United Nations International Children’s Emergency Fund (UNICEF) at the negotiated price after its Yizhuang-based Vaccine Workshop is built and has its vaccines “pre-qualified” by the WHO.

The report not only highlights the domestic and international operating environment, overall situation and market supply & demand of Chinese human vaccine industry, and market segments and prospects of 10 vaccines, but also analyzes the competition pattern, as well as operation, advantages and new product R&D dynamics of 11 human vaccine manufacturers.

Affected by the economic level, the national vaccination policy and the public awareness of epidemic prevention, the real vaccination is still mainly concentrated in EPI vaccine. The ratio between the lot release quantity of EPI and Extra EPI vaccine was 3:1 in 2010 which was raised to 4:1 in 2011, similar to that in 2009. Additionally, EPI vaccine market in China is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological and Biological Products Institutes in Changchu, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology Chinese Academy of Medical Sciences. In 2011, the state-owned companies accounted for 86.4% market share (by lot release quantity), and even occupied more than 99% market share in OPV segment.

Along with the gradual easing of access to vaccine market, the private firms enjoy the rising share in Extra EPI vaccine market. In 2011, in terms of lot release quantity, private enterprises made up as high as 52% market share and occupied 98.9% share in human Rabies Vaccine market. Meanwhile, the foreign companies maintain 15-20% market share (by lot release) by virtue of their technologies and product advantages. Stimulated by the robust demand for vaccines from Chinese market, five vaccine giants including GSK, Pfizer, Sanofi Pasteur, Merk and Novartis aggressively expand their business in China.

In January 2011, Merk acquired 100% equities of Beijing Skywing Bio-Tech, a player in the vaccine upstream sector. In March 2011, Novartis’ acquisition on 85% stake of Zhejiang Tianyuan was approved. In June 2011, GSK projected £24 million for 51% shares of GlaxoSmithKline-Neptunus. At the end of 2011, the joint venture between GSK and Walvax Biotechnology---GSK-Walvax Influenza Vaccine (Split Virion) Project was in the civil construction phase.
1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry 
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment 
2.2.3 Biopharmaceutical Market 
2.3 Status Quo
2.4 Supply & Demand
2.5 Competition Pattern
2.6 Prospect & Dynamics
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Market Price
3.2 Meningococcal Vaccines
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Rabies Vaccine
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.7.3 Market Price
3.8 Pneumococcal Vaccine
3.8.1 Supply & Demand
3.8.2 Competition Pattern
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply & Demand
3.9.2 Competition Pattern
3.9.3 Market Dynamics & Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply & Demand
3.10.2 Competition Pattern

4. Import and Export of Human Vaccine in China
4.1 Export
4.1.1 Export Volume & Value
4.1.2 Export Destinations
4.2 Import
4.1.1 Import Volume & Value
4.2.2 Country/Region of origin

5. Major Human Vaccine Manufacturers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Client and Supplier
5.2.6 R&D and Investment
5.2.7 Vaccine Business
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Client
5.3.6 R&D and Investment
5.4 Walvax Biotechnology Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Client and Supplier
5.4.6 R&D and Investment
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Client
5.6.6 Vaccine Business
5.7 Changchun BCHT Biotechnology Co., Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
Classification of Vaccines
Vaccine Industry Chain
EPI Human Vaccine Varieties in China, 2011
Global Human Vaccine Market Size, 2007-2011 
Sales of Global Top 5 Human Vaccine Manufacturers, 2007-2011 
R &D of New Vaccines Worldwide, 2009-2012
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2011
Policies Concerning Vaccine Industry in China
Sales Value and Total Profit of Biological & Biochemical Product Industry in China, 2008- 2011
Market Size of Human Vaccine in China, 2007-2011
Major Human Vaccine Varieties and Producers in China
Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2011
Lot Release Quantity and Proportion of EPI and Extra EPI Vaccines in China, 2007-2011
EPI Human Vaccine Market Share in China by Lot Release Quantity, 2007-2011
Extra EPI Human Vaccine Market Share in China by Lot Release Quantity, 2007-2011
R &D of New Human Vaccine in China by the End of Mar. 2012
Events Related to Vaccine Business of Foreign Corporations in China, 2011-2012
Vaccine Distribution Channel in China
Lot Release Quantity of Hepatitis B Vaccine in China by Dosage Form, 2007-2011 
Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Quantity in China, 2007-2011 
Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Quantity in China, 2007-2011
Market Prices of Hepatitis B Vaccine in Some Regions of China, 2012
Meningitis Morbidity and Mortality in China, 2008-2011
Lot Release Quantity of Meningococcal Vaccines in China by Type, 2007-2011 
Suppliers and Lot Release Quantity of A Meningococcal Vaccine, 2007-2011 
Suppliers and Lot Release Quantity of A+C Meningococcal Vaccine, 2007-2011
Suppliers and Lot Release Quantity of ACYW135 Meningococcal Vaccine in China, 2008-2011
Market Price of Meningococcal Vaccines in Some Regions of China, 2012 
Consumption Forecast of A-MCV, A+C-MCV and ACYW135 Meningococcal Vaccine in China, 2012-2015E 
Hepatitis A Morbidity and Mortality in China, 2008-2011
Hepatitis A Vaccine Lot Release Quantity in China, 2007-2011 
Hepatitis A Vaccine Suppliers and Lot Release Quantity in China, 2007-2011
Market Price of Hepatitis A Vaccine in China, 2012 
Consumption Forecast of Hepatitis A Vaccine in China, 2012-2015E
Influenza Morbidity and Mortality in China, 2008-2011
H1N1 Influenza Morbidity and Mortality in China, 2009-2011
Lot Release Quantity of Influenza Vaccine in China, 2007-2011 
Suppliers and Lot Release Quantity of Influenza Split Vaccine in China, 2007-2011 
Influenza Subunit Vaccine Suppliers and Lot Release Quantity in China, 2007-2011 
Market Price of Influence Vaccine in China, 2012
Hib Vaccine Lot Release Quantity in China, 2007-2011 
Hib Vaccine Suppliers and Lot Release Quantity in China, 2007-2011 
Market Price of Hib Vaccine in Some Regions of China, 2012
Sales Volume Forecast of Hib Vaccine in China, 2012-2015E
Rabies Morbidity and Mortality in China, 2007-2011
Human Rabies Vaccine Lot Release Quantity in China, 2007-2011 
Human Rabies Vaccine Lot Release Quantity in China by Type, 2007-2011 
Human Vero Cell Rabies Vaccine Suppliers and Lot Release Quantity in China, 2007-2011 
Human BHK Cell Rabies Vaccine Suppliers and Lot Release Quantity in China, 2007-2011
Market Price of Human Rabies Vaccine in Some Regions of China, 2012
Sales Volume Forecast of Human Rabies Vaccine in China, 2012-2015E
Varicella Vaccine Lot Release Quantity in China, 2007-2011
Suppliers and Lot Release Quantity of Varicella Vaccine in China, 2007-2011 
Market Price of Varicella Vaccine in Some Regions of China, 2012 
Lot Release Quantity of Pneumococcal Vaccine in China, 2007-2011
Suppliers and Lot Release Quantities of 7-valent and 23-valent Pneumococcal Vaccines in China, 2007-2011
Market Price of Pneumococcal Vaccines in Some Regions of China, 2012
DTP Vaccine Lot Release Quantity in China, 2007-2010 
DTPa Vaccine Suppliers and Lot Release Quantity in China, 2007-2011
Poliomyelitis Vaccine Lot Release Quantity in China, 2007-2011
Poliomyelitis Vaccine Suppliers and Lot Release Quantity in China, 2007-2011 
Export Volume & Value of Human Vaccine in China, 2009- 2011
Average Export Price of Human Vaccine in China, 2009- 2011
Export Destinations of Chinese Human Vaccines, 2011
Import Volume & Value of Human Vaccine in China, 2009-2011
Average Import Price of Human Vaccine in China, 2009-2011
Import Origins of Human Vaccine in China, 2011
Major Controlled Companies of Tiantan Biological and Their Revenue and Net Income 
Revenue and Total Profit of Tiantan Biological, 2007-2012
Revenue of Tiantan Biological by Product, 2007-2011
Revenue of Tiantan Biological by Region, 2007-2011
Gross Margin of Tiantan Biological by Product, 2007-2011
Tiantan Biological’s Procurement from Top 5 Suppliers and Proportion in Total Procurement, 2007-2011
Contribution of Top 5 Clients to Revenue of Tiantan Biological, 2007-2011
Top 5 Clients of Tiantan Biological and Their Contribution in Sales, 2011
Vaccine Revenue and Gross Margin of Tiantan Biological, 2007-2011
Lot Release Quantity and Proportion of Tiantan Biological’s Vaccines, 2009-2011
Revenue and Total Profit of Hualan Biological, 2007-2011
Revenue of Hualan Biological by Industry, 2007-2011
Revenue Structure of Hualan Biological by Industry, 2007-2011
Revenue of Hualan Biological by Product, 2007-2011
Revenue Structure of Hualan Biological by Product, 2007-2011
Revenue of Hualan Biological by Region, 2007-2011
Revenue Structure of Hualan Biological by Region, 2007-2011
Gross Margin of Hualan Biological by Industry, 2007-2011
Gross Margin of Hualan Biological by Product, 2007-2011
Hualan Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Hualan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2011
Lot Release Quantity and Proportion of Hualan Biological’s Vaccines, 2009-2011
Vaccine Revenue and Gross Margin of Hualan Biological, 2007-2011
Events Related to Vaccine Business of Hualan Biological, 2011-2012
Main Products of Zhifei Biological and Its Subsidiaries
Revenue and Profit of Zhifei Biological, 2007-2011
Revenue of Zhifei Biological by Product, 2010-2011
Lot Release Quantity and Proportion of Zhifei Biological’s Vaccines, 2011
Revenue of Zhifei Biological by Region, 2009-2011
Gross Margin of Zhifei Biological by Product, 2007-2011
Zhifei Biological’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
R&D Costs and % of Total Revenue of Zhifei Biological, 2008-2011
New Vaccine Development Schedule of Zhifei Biological, 2011-2013
Released Vaccines and Capacity of Walvax Biotechnology
Revenue and Profit of Walvax Biotechnology, 2007-2011
Revenue of Walvax Biotechnology by Product, 2007-2011
Lot Release Quantity and Proportion of Walvax Biotechnology’s Vaccines, 2009-2011
Revenue of Walvax Biotechnology by Region, 2010-2011
Gross Margin of Walvax Biotechnology, 2007-2011
Walvax Biological’s Revenue from Top 5 Clients and Its Procurement from Top 5 Suppliers, 2007-2011
Name List and Revenue Contribution of Walvax Biological’s Top 5 Clients, 2011
Name List and Procurement Contribution of Walvax Biological’s Top 5 Suppliers, 2011
R&D Costs and % of Total Revenue of Walvax Biological, 2009-2011
On-going New Vaccine R&D of Walvax Biological, as of Dec. 31, 2011
Revenue and Profit of Sinovac Biotech Ltd., 2007-2011
Revenue of Sinovac Biotech Ltd. by Product, 2007-2011
Lot Release Quantity and Proportion of Sinovac Biotech Ltd.’s Vaccines, 2008-2011
Gross Margin of Sinovac Biotech Ltd., 2007-2011
R&D Costs and % of Total Revenue of Sinovac Biotech Ltd., 2007-2011
Revenue and Net Income of Liaoning Chengda, 2007-2011
Revenue of Liaoning Chengda by Industry, 2007-2011
Revenue Structure of Liaoning Chengda by Industry, 2007-2011
Revenue of Liaoning Chengda by Region, 2007-2011
Revenue Structure of Liaoning Chengda by Region, 2007-2011
Gross Margin of Liaoning Chengda by Industry, 2007-2011
Liaoning Chengda’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Lot Release Quantity and Proportion of Chengda Biotechnology’s Vaccines, 2009-2011
Human Rabies Vaccine Sales of Liaoning Chengda, 2009-2011
Vaccine Gross Margin of Liaoning Chengda, 2009-2011
Vaccine Sales and Total Profit of Liaonig Chengda, 2009-2011
Revenue and Total Profit of Changchun BCHT, 2009-2011
Lot Release Quantity and Proportion of Changchun BCHT’s Vaccines, 2009-2011
Lot Release Quantity and Proportion of Changchun Changsheng’s Vaccines, 2008-2011
Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical
Lot Release Quantity and Proportion of Zhejiang Tianyuan Bio-Pharmaceutical’s Vaccines 
Lot Release Quantity and Proportion of Kangtai Biological’s Vaccines, 2008-2011 
Lot Release Quantity and Proportion of Hissen Bio-pharm’s Vaccines, 2009-2011
Vaccine Projects of Hissen Bio-pharm, 2011

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

China Pharmaceutical Equipment Industry Report, 2011-2012

In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales volume. According to Chin...

China Animal Vaccine Industry Report, 2010-2011

China animal vaccine industry has been fast-growing. The market maintained an average annual growth rate up to 13.6% in 2006-2010, and reached around RMB 7.5 billion in 2010, up 21.0% YoY. With the in...

China Human Vaccine Industry Report, 2010-2011

With the improvement of economy and people’s disease prevention awareness, China’s human vaccine market has expanded in recent years, growing at a CAGR of 24.0% in 2007-2010. In particular, the market...

China Pharmaceutical Chain Industry Report, 2010

Recent years have seen rapid growth of China’s pharmaceutical retail market, with expanding scale of chain enterprises and increasing number of drugstores, thanks to a fast-growing pharmaceutical indu...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号